Stockscreener 앱 받기
110.66
2.33%
2.52
시간 외 거래:
110.66
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome Therapeutics at Jefferies: Strategic Growth and Pipeline Expansion - Investing.com
Oppenheimer Initiates Coverage of Axsome Therapeutics (LSE:0HKF) with Outperform Recommendation - Nasdaq
2 Soaring Stocks Wth More Upside Potential - AOL.com
2 Soaring Stocks Wth More Upside Potential - The Motley Fool
111 Capital Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report? - Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Oppenheimer - Defense World
Morgan Stanley Remains Bullish on Axsome (AXSM), Reiterates $190 PT - MSN
Two Sigma Advisers LP Raises Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4.88 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Ameriprise Financial Inc. Has $1.54 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Oppenheimer Initiates Coverage of Axsome Therapeutics (BMV:AXSM) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Coverage of Axsome Therapeutics (BIT:1AXSM) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Coverage of Axsome Therapeutics (AXSM) with Outperform Recommendation - Nasdaq
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman Sells 3,750 Shares of Stock - MarketBeat
Oppenheimer Initiates Axsome Therapeutics (AXSM) with Outperform Rating - GuruFocus
Axsome Therapeutics Headed for Positive Growth With Ample Pipeline , Oppenheimer Says in New Research - marketscreener.com
Oppenheimer Initiates Coverage on Axsome Therapeutics (AXSM) wit - GuruFocus
Axsome initiated with Outperform at Oppenheimer (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics (AXSM) Gains Positive Outlook with Analyst C - GuruFocus
Oppenheimer Initiates Axsome Therapeutics at Outperform With $185 Price Target - marketscreener.com
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of AXSM, ET and APPS - ACCESS Newswire
Mark L. Jacobson Sells 20,673 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
Q2 EPS Forecast for Axsome Therapeutics Boosted by Analyst - MarketBeat
Mark L. Jacobson Sells 20,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
Ameriprise Financial Inc. Sells 179,697 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
How To Trade (AXSM) - news.stocktradersdaily.com
TFG Asset Management GP Ltd Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Trimmed by Wellington Management Group LLP - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for AXSM - Defense World
Hedge Fund and Insider Trading News: Chris Rokos, Ray Dalio, Paul Marshall, Edward Charles Molson, Third Point, Soroban Capital Partners, Whale Rock Capital Management, Elliott Management, Vestis Corp (VSTS), Axsome Therapeutics Inc (AXSM), and - Insider Monkey
Axsome Therapeutics Sets Strong Institutional Presence with Three Elite Healthcare Conference Presentations - Stock Titan
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Nuveen Asset Management LLC Increases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
ProShare Advisors LLC Acquires 2,942 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares By Investing.com - Investing.com India
Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares - Investing.com Australia
Axsome Therapeutics Secures US$570 Million Financing and Equity Investment from Blackstone - Global Legal Chronicle
Axsome settles patent dispute with Hetero Labs over Sunosi generic - MSN
Axsome Unveils Breakthrough Data from 3 CNS Programs: New Results for Depression, Alzheimer's, and Sleep Disorders - Stock Titan
Axsome, Hetero Settle Patent Fight on Daytime-Sleepiness Drug - Bloomberg Law News
Axsome and Hetero settle patent fight over sleep disorder drug - Endpoints News
Axsome's solriamfetol shows mixed results amid 13 phase III wins in April - BioWorld MedTech
Axsome Therapeutics (AXSM) Resolves Patent Dispute Over Sunosi G - GuruFocus
Axsome Reaches Settlement With Hetero Labs Over Sunosi Patent Dispute; Shares Up Pre-Bell - marketscreener.com
Axsome Therapeutics Settles Sunosi Patent Litigation With Hetero Labs - marketscreener.com
Axsome settles patent lawsuit with Hetero over SUNOSI By Investing.com - Investing.com Nigeria
Axsome settles Sunosi patent dispute with Hetero (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics (AXSM) Settles Patent Dispute Over SUNOSI | - GuruFocus
Axsome Therapeutics Settles Patent Litigation on SUNOSI - TipRanks
Axsome Agrees With Hetero Labs To Settle Patent Litigation Related To SUNOSI - Nasdaq
Axsome settles patent lawsuit with Hetero over SUNOSI - Investing.com
0.86%
1.24%
자본화:
|
볼륨(24시간):